Skip to main navigation
  • mail icon
  • fb icon
  • linkedin icon

Eiger - Header Menu

  • About
    • Team
  • Investors
    • Stock Information
    • Press Releases
    • Events & Presentations
    • SEC Filings
    • Corporate Governance
    • Shareholder Services
    • Analyst Coverage
  • Programs
    • Avexitide for Post-Bariatric Hypoglycemia (PBH)
    • Avexitide for Congenital Hyperinsulinism (CHI)
    • Lonafarnib / Ritonavir for Hepatitis Delta Virus (HDV) Infection
  • Resources
    • Expanded Access Policy
    • Contact Us
    • Privacy Policy
    • Terms of Use

Eiger - Header Menu

  • About
    • Team
  • Investors
    • Stock Information
    • Press Releases
    • Events & Presentations
    • SEC Filings
    • Corporate Governance
    • Shareholder Services
    • Analyst Coverage
  • Programs
    • Avexitide for Post-Bariatric Hypoglycemia (PBH)
    • Avexitide for Congenital Hyperinsulinism (CHI)
    • Lonafarnib / Ritonavir for Hepatitis Delta Virus (HDV) Infection
  • Resources
    • Expanded Access Policy
    • Contact Us
    • Privacy Policy
    • Terms of Use

Investors

Press Releases

Date
Latest Press Release

November 9, 2023

Eiger BioPharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

September 12, 2023

Eiger to Discontinue Phase 3 LIMT-2 Trial of Peginterferon Lambda in Patients with Chronic Hepatitis Delta

August 14, 2023

Eiger BioPharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update

June 29, 2023

Eiger BioPharmaceuticals to Focus on Metabolic Diseases with Avexitide; David Apelian Takes Helm as CEO

June 28, 2023

Eiger BioPharmaceuticals to Host Business Update Call Tomorrow

May 11, 2023

Eiger BioPharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update

May 3, 2023

Eiger BioPharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

April 13, 2023

Eiger BioPharmaceuticals Strengthens Management Team with New Appointments

March 16, 2023

Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

February 8, 2023

New England Journal of Medicine Publishes Positive Phase 3 TOGETHER Results with Peginterferon Lambda in COVID-19

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • …
  • Next page next ›
  • Last page last »

Tools

  • Print Page
  • Contact Us
  • RSS Feeds
  • Email Alerts
  • IR Contacts

Contact Us

Use of this website is governed by the Terms and Conditions and Privacy Policy.

Copyright ©2019 Eiger BioPharmaceuticals. All Rights Reserved. 06/19 XX-XX-XXXX

Contact Us

Eiger Logo

Use of this website is governed by the Terms and Conditions and Privacy Policy.

Copyright ©2019 Eiger BioPharmaceuticals. All Rights Reserved. 06/19 XX-XX-XXXX